The results showed that both the volumes and weights of the tumors in the PRMT5 knockdown groups were significantly decreased (Figure 2A-C) and conferred a marked survival benefit when compared with those of the control group (Figure 2D), demonstrating that the lack of PRMT5 suppressed the tumorigenicity of cervical cancer in vivo. The gene discussed is PRMT5; the disease is cervical cancer.